BMI predicts post-RP metastasis, prostate cancer mortalityBody mass index is an independent predictor of metastasis and prostate cancer mortality after radical prostatectomy, according to results from a large, long-term single-institution study.
URS techniques: When to choose dusting vs. basketingWhen treating kidney stones, debate continues over the use of dusting versus basketing. In this interview, Olivier Traxer, MD, describes both methods, lists his preferred laser settings, and explains why he changed the way he uses ureteral access sheaths.
Streamlined management of Peyronie’s disease
Streamlined management of Peyronie’s diseaseIn this article, we describe our thought processes in treating patients with Peyronie's disease, which are summarized in an algorithm.
ADT+EBRT improves OS in men with post-RP LN metastases"While improving local control seems to be important, especially in those with high-risk features, it’s not clear whether adjuvant EBRT is necessarily better than early salvage EBRT," writes Badar M. Mian, MD.
Study: Monopolar TURP utilization on the declineAlthough monopolar transurethral resection of the prostate remains the standard of care for bladder outlet obstruction secondary to BPH, its utilization has decreased in recent years, according to a recent study.
PCa-specific mortality not affected by comorbidityComorbidity does not affect prostate cancer-specific mortality, according to authors of a large prospective observational study of men in Sweden, published in the Journal of Clinical Oncology (2017; 35:3566-74).
2017 tax law: Here are the changes you can expectHere is a brief overview of the Tax Cuts and Jobs Act passed by Congress.
What new technology will you adopt in 2018?“My practice has seen a tremendous increase in patients’ awareness of HIFU as a treatment option," says one urologist.
Change to Part B pay draws specialty ireSeveral medical societies, including the AUA and the American Society of Clinical Oncology, are urging congressional leaders to prevent CMS from applying MIPS adjustments to Part B drug payments.
BLC scores well against WLC in recurrent bladder tumorsFluorescent blue light cystoscopy improves 3-year recurrence-free survival rates in patients with recurrent bladder tumors compared to white light cystoscopy, and researchers believe its use should be expanded.